Babushok Daria V, Duke Jamie L, Xie Hongbo M, Stanley Natasha, Atienza Jamie, Perdigones Nieves, Nicholas Peter, Ferriola Deborah, Li Yimei, Huang Hugh, Ye Wenda, Morrissette Jennifer J D, Kearns Jane, Porter David L, Podsakoff Gregory M, Eisenlohr Laurence C, Biegel Jaclyn A, Chou Stella T, Monos Dimitrios S, Bessler Monica, Olson Timothy S
Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104.
Comprehensive Bone Marrow Failure Center, Department of Pediatrics, Children's Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, PA 19104.
Blood Adv. 2017 Oct 10;1(22):1900-1910. doi: 10.1182/bloodadvances.2017010918.
Acquired aplastic anemia (aAA) is an acquired deficiency of early hematopoietic cells, characterized by inadequate blood production, and a predisposition to myelodysplastic syndrome (MDS) and leukemia. Although its exact pathogenesis is unknown, aAA is thought to be driven by Human Leukocyte Antigen (HLA)-restricted T cell immunity, with earlier studies favoring HLA class II-mediated pathways. Using whole exome sequencing (WES), we recently identified two aAA patients with somatic mutations in HLA class I genes. We hypothesized that HLA class I mutations are pathognomonic for autoimmunity in aAA, but were previously underappreciated because the Major Histocompatibility Complex (MHC) region is notoriously difficult to analyze by WES. Using a combination of targeted deep sequencing of HLA class I genes and single nucleotide polymorphism array (SNP-A) genotyping we screened 66 aAA patients for somatic HLA class I loss. We found somatic HLA loss in eleven patients (17%), with thirteen loss-of-function mutations in *33:03, *68:01, *14:02 and *40:02 alleles. Three patients had more than one mutation targeting the same HLA allele. Interestingly, *14:02 and *40:02 were significantly overrepresented in aAA patients, compared to ethnicity-matched controls. Patients who inherited the targeted HLA alleles, regardless of HLA mutation status, had a more severe disease course with more frequent clonal complications as assessed by WES, SNP-A, and metaphase cytogenetics, and more frequent secondary MDS. The finding of recurrent HLA class I mutations provides compelling evidence for a predominant HLA class I-driven autoimmunity in aAA, and establishes a novel link between aAA patients' immunogenetics and clonal evolution.
获得性再生障碍性贫血(aAA)是一种早期造血细胞的获得性缺陷,其特征为血液生成不足,且易发展为骨髓增生异常综合征(MDS)和白血病。尽管其确切发病机制尚不清楚,但aAA被认为是由人类白细胞抗原(HLA)限制的T细胞免疫驱动的,早期研究更倾向于HLA II类介导的途径。通过全外显子组测序(WES),我们最近在两名aAA患者中发现了HLA I类基因的体细胞突变。我们推测HLA I类突变是aAA自身免疫的特征性表现,但此前未得到充分认识,因为主要组织相容性复合体(MHC)区域通过WES分析非常困难。我们结合HLA I类基因的靶向深度测序和单核苷酸多态性阵列(SNP-A)基因分型,对66例aAA患者进行了体细胞HLA I类缺失筛查。我们在11例患者(17%)中发现了体细胞HLA缺失,在*33:03、*68:01、14:02和40:02等位基因中有13个功能丧失突变。3例患者针对同一HLA等位基因有多个突变。有趣的是,与种族匹配的对照组相比,14:02和40:02在aAA患者中显著富集。通过WES、SNP-A和中期细胞遗传学评估,无论HLA突变状态如何,继承靶向HLA等位基因的患者疾病进程更严重,克隆并发症更频繁,继发性MDS也更频繁。反复出现的HLA I类突变的发现为aAA中主要由HLA I类驱动的自身免疫提供了有力证据,并在aAA患者的免疫遗传学和克隆进化之间建立了新的联系。